Evaluation of Dienogest Pharmacokinetics and Safety in Women with Endometriosis and Diverse Genetic Variants

The primary objective of this study is to evaluate the **safety** and **pharmacokinetics** of **dienogest** in women with different gene variants. This is clinically relevant as it aims to personalize treatment for **endometriosis**, potentially improving therapeutic outcomes and minimizing adverse effects. The study involves healthy volunteers to assess the impact of genetic differences on the drug's behavior in the body.

The clinical trial involves **healthy volunteers** as the study population, specifically focusing on females. The age range of participants is categorized under code "3," which typically represents a specific age group, though the exact range is not provided. The trial does not include a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected based on their health status as healthy individuals, with no specific lifestyle considerations such as diet or physical activity mentioned. The trial does not include male subjects, and no significant inclusion or exclusion criteria have been detailed by the sponsor.

The clinical trial is designed as a **Phase 3** study involving **healthy volunteers** to evaluate the safety and kinetics of a treatment. The trial is structured as a randomized, double-blind, controlled study to ensure the reliability and validity of the results. The estimated recruitment start date is March 1, 2025, with an anticipated end date of August 31, 2025, indicating a total trial duration of approximately six months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to ensure participants meet the necessary health standards for inclusion. Following successful screening, participants will be randomly assigned to either the treatment or control group, maintaining the double-blind nature of the study.

Throughout the trial, participants will attend regular follow-up visits to monitor their health status and collect data on the treatment's effects. These visits are crucial for assessing the primary and secondary endpoints of the study, although specific endpoints are not detailed in the available data. The sequence and frequency of these visits will be determined by the study protocol to ensure consistent data collection and participant safety.

The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the treatment's impact. The expected length of participant involvement is aligned with the overall trial duration, subject to individual adherence to the study protocol. Conditions that may lead to early termination from the study include adverse reactions, non-compliance with study procedures, or withdrawal of consent by the participant.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Additionally, details about drug administration, dosing schedules, and participant compliance monitoring are not included in the source data. As such, no further information can be offered regarding the substances used in this study.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on March 1, 2025, with an estimated completion date of August 31, 2025. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology for measuring, collecting, and analyzing these efficacy parameters, consistent with the standards of Phase 3 clinical trials. The trial's design and execution will adhere to rigorous scientific and ethical standards to ensure the reliability and validity of the efficacy assessments.